Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNTech SE (BNTX) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and annual reports on Form 20-F. As a foreign private issuer listed on Nasdaq, BioNTech uses these filings to report financial results, material agreements, strategic transactions and key corporate presentations.
Through its 6-K filings, BioNTech has furnished quarterly financial statements and operating reviews, detailing revenues from its COVID-19 vaccine franchise, collaboration income and research and development spending related to its oncology and mRNA programs. Other 6-Ks incorporate press releases and presentations covering topics such as third quarter results, R&D and AI-focused events, and strategic business updates presented at investor conferences.
Regulatory filings also document major corporate transactions and collaborations. For example, BioNTech has filed 6-Ks that attach press releases on its public exchange offer for all outstanding shares of CureVac N.V. and the subsequent completion of that acquisition, as well as a detailed description of the amended and restated global co-development and co-commercialization agreement with Bristol Myers Squibb for the bispecific antibody pumitamig (BNT327/BMS986545). These documents outline development responsibilities, cost-sharing, profit and loss sharing and intellectual property licensing arrangements.
Investors can use this page to review filings related to clinical and strategic milestones, including R&D day presentations, AI strategy updates and oncology pipeline overviews that are furnished as exhibits to Form 6-K. Stock Titan enhances access to these materials by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy documents such as financial reports, collaboration agreements and transaction-related disclosures.
For those researching BNTX stock, the filings page is a resource for understanding how BioNTech describes its business, reports its financial performance, and records significant agreements and acquisitions in the official SEC record.
BioNTech SE Chief Executive Officer Ugur Sahin filed an initial ownership report detailing his direct, indirect and derivative interests in the company’s ordinary shares. The filing shows indirect ownership of 40,132,788 ordinary shares held through Medine GmbH, which he wholly owns and may be deemed to beneficially own. It also lists 858,209 ordinary shares held directly.
In addition, Sahin holds several option and phantom option awards and performance share units tied to BioNTech ordinary shares, with various exercise prices and expiration dates extending to 2035. These awards generally vest in equal annual installments over four years and are subject to performance-based and other conditions.
BioNTech SE filed an initial beneficial ownership report for Chief Financial Officer Ramon Zapata Gomez on Form 3. This filing formally registers him as an officer subject to insider reporting rules. The available data shows no transactions or derivative positions reported in this Form 3 excerpt.
BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.
BioNTech SE filed an initial insider ownership report for Chief People Officer Kylie Jimenez. This Form 3 establishes her status as a reporting person under U.S. securities rules. The filing does not list any transactions or option exercises; it simply opens ongoing disclosure of future activity.
BioNTech SE is highlighting progress in its late-stage lung cancer portfolio with new clinical data to be presented at the European Lung Cancer Congress 2026 in Copenhagen. The company will showcase programs spanning immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies across multiple lung cancer settings.
Key updates include pumitamig, a PD-L1×VEGF-A bispecific immunomodulator with encouraging antitumor activity and survival outcomes in several Phase 1/2 trials in China, supporting ongoing global ROSETTA Lung-01 and Lung-02 trials. Gotistobart, a CTLA-4–targeting candidate, showed clinically meaningful antitumor activity and a 54% reduction in risk of death versus standard chemotherapy in stage 1 of the global Phase 3 PRESERVE-003 study in squamous NSCLC.
BioNTech also reported first clinical data for BNT326/YL202, a HER3-targeted ADC, in advanced NSCLC with antitumor activity and favorable safety, backing a combination trial with pumitamig. Overall, BioNTech is running 16 lung cancer trials, including four pivotal Phase 3 and five novel-novel combination studies.
BioNTech SE director Michael Motschmann has filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and, in the data provided, does not report any insider buy, sell, gift, or option exercise transactions.
BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares. He holds options and phantom options over 18,416, 25,459, 8,838, 7,112 and 14,664 underlying ordinary shares with exercise prices including 113.9400, 185.2300 and 152.1000, expiring between 2031 and 2035. He also reports 11,047 performance share units tied to ordinary shares. In addition, he has 141,514 ordinary shares directly, 449,387 ordinary shares held through Tofino GmbH, where he is sole shareholder, and 1,638 ordinary shares held by immediate family, for which he disclaims beneficial ownership except for any pecuniary interest.
BioNTech SE director Helmut Wolfgang Jeggle reported his initial ownership of the company’s ordinary shares. The Form 3 shows he holds 332,316 ordinary shares directly and 656,951 ordinary shares indirectly as of March 18, 2026. The indirect shares are held by Salvia GmbH, where he serves as Chief Executive Officer and may be deemed to beneficially own the shares held by that entity.
BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales. The filing lists option grants over 18,416, 25,459 and 9,306 underlying ordinary shares, phantom options over 7,112 and 14,664 shares, and 11,633 performance share units.
Footnotes explain that these options and PSUs generally vest in equal annual installments over four years and become exercisable four years after grant, subject to performance-based conditions tied to BioNTech’s share price and, for PSUs, its performance relative to the Nasdaq Biotechnology Index.
BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership. The filing reports indirect beneficial ownership of 1,927 ordinary shares.
The shares are held by beebusy Capital GmbH, where Wandschneider is the sole shareholder and may be deemed to beneficially own the shares. The filing does not report any recent share purchases or sales, only this existing position.